Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted 89Zr-Pertuzumab PET/CT

• DOI: 10.1148/radiol.2020192828
• Publication Date: 2020-06-09T13:56:42Z
• Authors: Gary A. Ulaner; Jorge A. Carrasqu...; Christopher C. Riedl; Randy Yeh; Vaios Hatzoglou; Dara S. Ross; Komal Jhaveri; Sarat Chandarlapaty; David M. Hyman; Brian M. Zeglis; Serge K. Lyashchenko; Jason S. Lewis
• Keywords: Pertuzumab; Primary tumor

Background Human epidermal growth factor receptor 2 (HER2)-targeted therapies are successful in patients with HER2-positive malignancies; however, spatial and temporal heterogeneity of HER2 expression may prevent identification optimal for these therapies. Purpose To determine whether imaging the HER2-targeted PET tracer zirconium 89 (89Zr)-pertuzumab can depict metastases women HER2-negative primary breast cancer. Materials Methods From January to June 2019, biopsy-proven cancer metastatic disease were enrolled a prospective clinical trial (ClinicalTrials.gov NCT02286843) underwent 89Zr-pertuzumab PET/CT noninvasive whole-biopsy evaluation potential metastases. 89Zr-pertuzumab-avid foci that suspicious tissue sampled examined by pathologic analysis document status. Results Twenty-four (mean age, 55 years ± 11 [standard deviation]) enrolled. Six demonstrated at disease. Of six women, three had metastases, two findings disease, one fine-needle aspirate inconclusive results. Conclusion 89-pertuzumab was detecting This demonstrates ability targeted identify might not otherwise be considered. © RSNA, 2020 Online supplemental material is available this article. See editorial Mankoff Pantel issue.